|Medical Services||Locations||Patient/Visitor Info||Programs & Support||Points of Pride|
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Last Modified: 6/5/2012 First Published: 5/6/2010
Eligibility criteriainclude the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will be randomly assigned (have an equal chance of being placed to) one of two treatment groups.
Patients in group one will receive everolimus by mouth once daily. Treatment may continue for 54 weeks.
Patients in group two will receive placebo by mouth once daily. Treatment may continue for 54 weeks.
After finishing treatment, patients will be evaluated every 6 months for 2 years and then once a year for 8 years.
Trial Contact Information
Blanche Reiner RN OCN 610-738-2515
Nona Blauvelt MSN AOCN 610-738-2522
Last Updated: 7/16/2012